Exact Sciences (EXAS) Misses Q1 EPS by 1c, Revs Beat; Raises Outlook

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.66), $0.01 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $162 million versus the consensus estimate of $153.04 million.

GUIDANCE:

Exact Sciences sees FY2019 revenue of $725-740 million, versus prior of $710-$730 million the consensus of $729.5 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'